Adrenocortical tumors an integrated clinical, pathologic, and molecular approach at the university of Michigan

Archives of Pathology and Laboratory Medicine

Volumn 134, Issue 10, 2010, Pages 1440-1443

  Giordano, Thomas J ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN C RECEPTOR;

ADRENAL CORTEX TUMOR; ANIMAL; ARTICLE; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; GENETICS; HUMAN; METHODOLOGY; MOUSE; PATHOLOGY; RESEARCH; STANDARD;

ADRENAL CORTEX NEOPLASMS; ANIMALS; GENE EXPRESSION PROFILING; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MICE; RECEPTOR, IGF TYPE 1; RESEARCH;

EID: 77958588047     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Conn JW. Primary aldosteronism. J Lab Clin Med. 1955;45(4):661-664.
2. Anonymous. William H. Beierwaltes: a life in nuclear medicine. J Nucl Med. 2000;41(10):19N-20N.
3. Sisson JC. Radiopharmaceuticals for nuclear endocrinology at the University of Michigan. Cancer Biother Radiopharm. 2000;15(4):305-318.
4. Newman EA, Guest AB, Helvie MA, et al. Changes in surgical management resulting from case review at a breast cancer multidisciplinary tumor board. Cancer. 2006;107(10):2346-2351.
5. Else T, Giordano TJ, Hammer GD. Evaluation of telomere length maintenance mechanisms in adrenocortical carcinoma. J Clin Endocrinol Metab. 2008;93(4):1442-1449.
6. Giordano TJ, Kuick R, Else T, et al. Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling. Clin Cancer Res. 2009;15(2):668-676.
7. Giordano TJ, Thomas DG, Kuick R, et al. Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. Am J Pathol. 2003;162(2):521-531.
8. Schteingart DE, Doherty GM, Gauger PG, et al. Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr Relat Cancer. 2005;12(3):667-680.
9. Aiba M, Fujibayashi M. Histopathological diagnosis and prognostic factors in adrenocortical carcinoma. Endocr Pathol. 2005;16(1):13-22.
10. Saeger W. Histopathological classification of adrenal tumours. Eur J Clin Invest. 2000;30(suppl 3):58-62.
11. Muller J. Adrenocortical tumors: clinical and diagnostic findings. Recent Results Cancer Res. 1990;118:106-112.
12. Lau SK, Weiss LM. The Weiss system for evaluating adrenocortical neoplasms: 25 years later. Hum Pathol. 2009;40(6):757-768.
13. Weiss LM. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am J Surg Pathol. 1984;8(3):163-169.
14. Terzolo M, Angeli A, Fassnacht M, et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med. 2007;356(23):2372-2380.
15. Bertherat J, Coste J, Bertagna X. Adjuvant mitotane in adrenocortical carcinoma [author reply in N Engl J Med. 2007;357(12):1259].
16. N Engl J Med. 2007;357(12):1256-1257.
17. Weiss LM, Medeiros LJ, Vickery AL Jr. Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol. 1989;13(3):202-206.
18. Boulle N, Logie A, Gicquel C, Perin L, Le Bouc Y. Increased levels of insulin-like growth factor II (IGF-II) and IGF-binding protein-2 are associated with malignancy in sporadic adrenocortical tumors. J Clin Endocrinol Metab. 1998; 83(5):1713-1720.
19. Gao ZH, Suppola S, Liu J, Heikkila P, Janne J, Voutilainen R. Association of H19 promoter methylation with the expression of H19 and IGF-II genes in adrenocortical tumors. J Clin Endocrinol Metab. 2002;87(3):1170-1176.
20. Gicquel C, Bertagna X, Gaston V, et al. Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Cancer Res. 2001;61(18):6762-6767.
21. Gicquel C, Bertagna X, Schneid H, et al. Rearrangements at the 11p15 locus and overexpression of insulin-like growth factor-II gene in sporadic adrenocortical tumors. J Clin Endocrinol Metab. 1994;78(6):1444-1453.
22. Gicquel C, Raffin-Sanson ML, Gaston V, et al. Structural and functional abnormalities at 11p15 are associated with the malignant phenotype in sporadic adrenocortical tumors: study on a series of 82 tumors. J Clin Endocrinol Metab. 1997;82(8):2559-2565.
23. Ilvesmaki V, Kahri AI, Miettinen PJ, Voutilainen R. Insulin-like growth factors (IGFs) and their receptors in adrenal tumors: high IGF-II expression in functional adrenocortical carcinomas. J Clin Endocrinol Metab. 1993;77(3):852-858.
24. Liu J, Kahri AI, Heikkila P, Ilvesmaki V, Voutilainen R. H19 and insulinlike growth factor-II gene expression in adrenal tumors and cultured adrenal cells. J Clin Endocrinol Metab. 1995;80(2):492-496.
25. Logie A, Boulle N, Gaston V, et al. Autocrine role of IGF-II in proliferation of human adrenocortical carcinoma NCI H295R cell line. J Mol Endocrinol. 1999;23(1):23-32.
26. Barlaskar FM, Spalding AC, Heaton JH, et al. Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma. J Clin Endocrinol Metab. 2009;94(1):204-212.